pfizer辉瑞品牌怎么样 申请店铺

我要投票 pfizer辉瑞在中草药行业中的票数:1703 更新时间:2026-02-11
pfizer辉瑞是哪个国家的品牌?「pfizer辉瑞」是 辉瑞投资有限公司 旗下著名品牌。该品牌发源于上海,由创始人苗天祥在1998期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力pfizer辉瑞品牌出海!将品牌入驻外推网,定制pfizer辉瑞品牌推广信息,可以显著提高pfizer辉瑞产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

pfizer辉瑞怎么样

辉瑞公司创建于1849年,迄今已有160多年的历史,总部位于美国纽约,是目前全球最大的以研发为基础的生物制药公司之一。

辉瑞生物制药在华上市的创新药物已超过50个,其治疗领域涵盖了心脑血管及代谢、抗感染、中枢神经、抗炎镇痛、抗肿瘤、泌尿、血液健康(包括血友病)等诸多领域。其中如立普妥®、络活喜®、万艾可®、舒普深®、大扶康®、希舒美®、索坦®、开普拓®、阿诺新®、任捷®、贝赋®等许多产品在市场上处于领先地位。为了让中国的广大患者能及时接受与全球同步的先进的药物治疗,辉瑞未来将进一步加大和加快在华新药引进和上市的力度和速度。

辉瑞健康药物旗下的善存®、钙尔奇®、惠菲宁®等消费保健产品也在中国市场家喻户晓,并以其优异的品质深受广大消费者的青睐。

自20世纪80年代进入中国以来,辉瑞目前已发展成为在华大型外资制药企业。辉瑞在中国有约10000多名员工,业务覆盖了全国250余个城市。辉瑞始终把“携手共创健康中国”作为在华的使命,承诺并积极参与促进中国医疗卫生事业的发展和提高人民健康水平。我们志在通过创新的、富有社会责任并且商业可行的方式,满足中国13亿人民多样化的医疗服务需求。除了提供广泛的创新医药健康产品组合外,辉瑞还积极与有关政府部门、科研/医疗机构、学术组织、社会团体等各方面合作,通过开展患者教育、疾病宣传、健康管理、社区医疗、人才培养等项目积极推动中国医疗卫生事业的发展。

Founded in 1849, Pfizer has a history of more than 160 years. Headquartered in New York, the company is one of the largest R & D-based biopharmaceutical companies in the world. Pfizer biopharmaceuticals has been listed in more than 50 innovative drugs in China, and its treatment fields cover cardio cerebrovascular and metabolism, anti infection, central nervous system, anti-inflammatory and analgesic, anti-tumor, urinary, blood health (including hemophilia) and many other fields. Among them, many products, such as Lipitor ®, luohuoxi ®, Viacom ®, shupushen ®, Dafukang ®, sisumi ®, sotan ®, keputuo ®, anoxin ®, Renjie ®, Beifu ®, are in the leading position in the market. In order to enable the vast number of patients in China to receive advanced drug treatment in time with the global synchronization, Pfizer will further increase and speed up the introduction and marketing of new drugs in China in the future. Pfizer's consumer health care products, such as Shancun ®, Caltech ®, and huifeining ®, are also well known in the Chinese market, and are favored by the majority of consumers with their excellent quality. Since entering China in 1980s, Pfizer has developed into a large foreign pharmaceutical enterprise in China. Pfizer has more than 10000 employees in China, covering more than 250 cities across the country. Pfizer has always taken "working together to create a healthy China" as its mission in China, committed to and actively participated in promoting the development of China's medical and health undertakings and improving the people's health level. We aim to meet the diverse needs of China's 1.3 billion people through innovative, socially responsible and commercially viable ways. In addition to providing a wide range of innovative pharmaceutical and health product portfolio, Pfizer also actively cooperates with relevant government departments, scientific research / medical institutions, academic organizations, social organizations and other aspects, and actively promotes the development of China's medical and health undertakings through patient education, disease publicity, health management, community medical care, talent training and other projects.

本文链接: https://brand.waitui.com/9f250b20b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

武商集团:股东达孜银泰拟减持不超3%股份

36氪获悉,武商集团公告,持股5%以上股东达孜银泰商业发展有限公司计划在公告披露之日起十五个交易日后的三个月内(2026年3月13日-2026年6月12日),以集中竞价和/或大宗交易方式减持公司股份不超过2249.71万股(占公司剔除回购专用账户后总股本的3%);其中集中竞价不超过749.90万股(1%),大宗交易不超过1499.81万股(2%);减持原因为资金周转需要,股份来源为协议转让取得。

57分钟前

美股大型科技股盘前涨跌互现,英伟达涨近1%

36氪获悉,美股大型科技股盘前涨跌互现,截至发稿,英伟达涨近1%,特斯拉涨0.71%,微软涨0.47%,亚马逊涨0.43%,Arm涨0.31%,奈飞涨0.05%,Meta涨0.01%;苹果跌0.46%,谷歌跌0.37%。

57分钟前

热门中概股美股盘前多数上涨,爱奇艺涨超1%

36氪获悉,热门中概股美股盘前多数上涨,截至发稿,爱奇艺涨超1%,理想汽车、腾讯音乐涨近1%,阿里巴巴涨0.79%,小鹏汽车涨0.74%,京东、拼多多涨0.5%;百度跌0.02%。

57分钟前

华森制药:股东刘小英拟减持不超3%股份

36氪获悉,华森制药公告,持股5%以上股东刘小英因个人资金需求,计划自公告披露之日起至15个交易日届满次日起的3个月内(即2026年3月13日至2026年6月12日),通过集中竞价方式减持不超过417.60万股(不超过公司总股本的1%),通过大宗交易方式减持不超过835.19万股(不超过公司总股本的2%),合计减持不超过1252.79万股,即不超过公司总股本的3%。

57分钟前

日科化学:股东赵东日拟减持不超3%公司股份

36氪获悉,日科化学公告,公司持股5%以上股东赵东日计划自2026年3月12日至2026年6月11日期间,通过集中竞价交易和大宗交易方式减持公司股份不超过1349.8万股,即不超过公司总股本的3%。减持价格将根据减持时的二级市场价格确定,减持原因为个人资金需求。本次减持计划实施具有不确定性。

57分钟前

本页详细列出关于pfizer辉瑞的品牌信息,含品牌所属公司介绍,pfizer辉瑞所处行业的品牌地位及优势。
咨询